Author | Tyvin A. Rich, MD


Modulation of Dose Intensity in Aerodigestive Tract Cancers: Strategies to Reduce Toxicity

December 01, 2001

ByTyvin A. Rich, MD|Alexander V. Kirichenko, MD, PhD|Rowley Sewell, BS, MBA|Martin Straume, PhD

Advances in diagnostic and therapeutic radiology and a better understanding of cell biology are being applied in practical ways to modulate treatment morbidity. Conformal radiotherapy targets the cancer precisely and can be combined with new systemically administered radiosensitizers.

Camptothecin Schedule and Timing of Administration With Irradiation

March 02, 2001

ByTyvin A. Rich, MD|Alexander V. Kirichenko, MD, PhD

The camptothecins are a new class of chemotherapeutic radiation sensitizers. Clinical trials with camptothecins alone show higher toxicity than predicted by preclinical models, which has created the challenge of finding new

Camptothecin Radiation Sensitization: Mechanisms, Schedules, and Timing

August 01, 1998

ByTyvin A. Rich, MD|Alexander V. Kirichenko, MD, PhD

Based on high tumoricidal activity of the camptothecin analogs topotecan (Hycamtin), irinotecan (CPT-11[Camptosar]), and 9-aminocamptothecin (9-AC) in preclinical studies, clinical trials began testing these agents

Combined Radiation and Chemotherapy for Carcinoma of the Anal Canal

March 01, 1998

ByTyvin A. Rich, MD

Sphincter-preserving treatment with combined radiation and chemotherapy has replaced abdominoperineal resection as the standard of care for patients with carcinoma of the anal canal. Randomized studies have shown